article

Taking a collaborative approach to continuous pharmaceutical manufacturing

Offering increased yields, lower utility consumption and reduced waste, continuous manufacturing presents a paradigm shift in drug production and meets the pharmaceutical industry’s demands for faster product development, reduced costs, improved production economics and increased flexibility.

continuous manufacturing GEA

CONTINUOUS manufacturing (CM) is gaining momentum in the pharmaceutical industry, enabling a more efficient means of producing drugs. It entails moving away from stepwise and time-consuming batch processing — with the associated intermediate material transfer steps and frequent testing — to a fully integrated and closely-controlled process that gives excellent product consistency by intrinsic design.

Continuous production has a much smaller footprint, offers higher yields and lower environmental emissions per unit of product, while being far more flexible in operation. Typical applications include producing small batches of high-value products, reformulations and current non-robust processes and formulations with specific granulation and/or drying issues.

The rest of this content is restricted - login or subscribe free to access

Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Related topics

Related organisations

Send this to a friend